Option Care named a home provider of new ALS drug
September 6, 2017 - als
BANNOCKBURN — Option Care Enterprises, an eccentric provider of home and swap diagnosis site distillate services, has sealed an agreement to turn a inhabitant engaged home distillate provider for Radicava, an intravenous distillate diagnosis for amyotrophic parallel sclerosis.
Radicava, a initial ALS diagnosis choice authorized by a Food and Drug Administration in some-more than 20 years, is now accessible for studious diagnosis in a United States.
Sometimes referred to as Lou Gehrig’s disease, ALS is a fast on-going neurodegenerative condition in that a infancy of patients die within dual to 5 years of diagnosis. 1-2
“Our specialized clinical believe and severe caring government support — opposite mixed therapy areas and studious populations — are a fortitude of a imagination as a nation’s home distillate therapy personality for neuromuscular disorders like ALS,” pronounced John Rademacher, CEO of Option Care. “This imagination is because we are a devoted partner for innovators bringing to marketplace new therapies like Radicava. By partnering with manufacturers, who trust us to yield vicious pharmacy services and caring government support, we are means to yield unmatched home distillate services to a patients.”
Option Care’s inhabitant payer network includes contracts with some-more than 800 health plans, ensuring extended entrance to Radicava for patients and clinicians who rest on clinical government of home distillate therapy. Additionally, a inhabitant network of clinicians includes some-more than 1,800 nurses specifically lerned in caring coordination and customized clinical government of formidable conditions, including ALS. 3
Approved by a FDA in May 2017, Radicava is marketed and distributed by Mitsubishi Tanabe Pharma America.